The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

We’re all familiar with vaccines delivered by a needle into the arm. However, scientists at Stanford Medicine recently ...